Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Telmisartan (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
The primary objective of this survey is to prospectively investigate safety and efficacy in
patients with hypertension treated with telmisartan in proper use in medical practice over a
long period
Clinical Details
Official title: Post-Marketing Surveillance of Micardis® (Telmisartan) Special Drug Use-results Survey on Long-term Treatment
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Number of patients with adverse drug reactionsIncidence of adverse drug reactions Change in Mean systolic blood pressure (SBP) Change in Mean diastolic blood pressure (DBP)
Secondary outcome: Overall assessment of efficacy by investigator on 4-point scaleChange in pulse rate
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with hypertension
Exclusion Criteria:
Patients with the following conditions
- Patients with a history of hypersensitivity of this product
- Women in pregnancy (included the possibility of pregnancy)
- Patients with severe biliary obstructive disorders or severe hepatic insufficiency
Locations and Contacts
Additional Information
Starting date: September 2003
Last updated: September 16, 2014
|